Pharmafile Logo
Pharmafocus logo
Advanced Search

pharma

Showing 15 posts of 2914 posts found.

enrique_conterno

FibroGen names Lilly veteran as new CEO

January 7, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, fibrogen, pharma

Eli Lilly veteran Enrique Conterno has been revealed as the new Chief Executive Officer of FibroGen following the unexpected death …

Appointment
glenmark

FDA approves Glenmark’s generic version of Novartis’ Exjade tablets for chronic iron overload

January 7, 2020
Manufacturing and Production, Research and Development Glenmark, exjade, generic, pharma

Indian pharma firm Glenmark has announced it has secured approval from the FDA for its oral deferasirox tablets in the …

News
shutterstock_38078521

Bavencio extends survival at Phase 3 in previously untreated locally advanced or metastatic urothelial carcinoma

January 7, 2020
Manufacturing and Production, Research and Development Bavencio, Merck KGaA, Pfizer, pharma

Bavencio (avelumab), the anti-programmed death ligand-1 (PD-L1) antibody co-developed by Pfizer and Merck KGaA’s biopharma unit EMD Serono, has been …

News
teva_copy

Teva to settle bribery lawsuit with $54 million payout

January 7, 2020
Manufacturing and Production, Sales and Marketing Teva, bribery, pharma

Israeli drug firm Teva has agreed to settle an ongoing lawsuit levying allegations of the company’s bribery of doctors, it …

News
ipsen-logo-big

MHRA expands approval of Dysport for symptomatic treatment of focal spasticity of the upper limbs in paediatric cerebral palsy

January 6, 2020
Sales and Marketing Dysport, MHRA, ipsen, pharma

Ipsen has secured an expansion in the UK to the existing label for Dysport (lemborexant), with the Medicines and Healthcare …

News
stock-incyte-01-shutter

Incyte’s drug stumbles at Phase 3 in treatment-naive acute graft-versus-host disease

January 6, 2020
Research and Development, Sales and Marketing Incyte, pharma, trial failure

Drugmaker Incyte has made it known that its selective JAK1 inhibitor therapy itacitinib fell short at Phase 3 in the …

News
roche

Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma

December 16, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Roche, melanoma, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when …

News
insider_interview_andrew_roach

A new weapon against Parkinson’s-related psychosis

December 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, cannabidiol, cannabis, feature, pharma

Dr Arthur Roach, Director of Research at the charity Parkinson’s UK, discusses new trials on cannabidiol in the treatment of …

Feature
shutterstock_gonnorrhea

Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate

December 16, 2019
Research and Development, Sales and Marketing Cancer, Transgene, lung cancer, pharma

Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line …

News

Novartis pulls fevipiprant development in asthma following trial failure

December 16, 2019
Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, pharma, trial failure

Novartis has made it known that its DP2 receptor antagonist fevipiprant failed at Phase 3 to show clinically relevant levels …

News

Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure

December 16, 2019
Research and Development, Sales and Marketing Biogen, pharma, trial failure

Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed …

News

Pfizer’s Vyndaqel scores CHMP support for transthyretin amyloidosis in cardiomyopathy patients

December 16, 2019
Sales and Marketing Pfizer, Vyndaqel, pharma

Pfizer’s once-daily 61mg oral capsule formulation of Vyndaqel (tafamidis) has secured a positive opinion from the European Medicines Agency’s (EMA) …

News
darzalex-product-shot---100mg-vial-2-hr

Genmab’s Darzalex secures CHMP recommendation in Europe for front-line multiple myeloma

December 13, 2019
Medical Communications, Sales and Marketing CHMP, Genmab, darzalex, pharma

The Committee for Medicinal Products for Human Use (CHMP), an advisory panel for the European Medicines Agency, has given its …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

December 13, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top ten

As the UK reels from the news that Boris Johnson and the Conservative Party have stormed the general election and …

News
novartis_window

Novartis’ Beovu scores CHMP recommendation after proving non-inferior to Eylea in wet age-related macular degeneration

December 13, 2019
Medical Communications, Sales and Marketing Beovu, EMA, Novartis, pharma

Novartis’ single-chain antibody fragment Beovu has secured recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use …

News
The Gateway to Local Adoption Series

Latest content

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026

Alvotech appoints Lisa Graver as CEO

February 3, 2026

HonorHealth Research Institute announces first patient dosed with new stroke treatment

February 2, 2026

Accord Healthcare appoints Paul Burden as Associate Vice President and Country Head UK

February 2, 2026

Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases

January 30, 2026